Daliresp is an anti-COPD drug owned by Astrazeneca. The active ingredient in Daliresp is roflumilast. The drug was first authorized for market use on February 28, 2011 and is available as a tablet for oral use.
The generic version of Daliresp is predicted to be released after March 8, 2024. This release is based on the expiration date of the last patent held by AstraZeneca for Daliresp.
Daliresp is used to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The active ingredient, roflumilast, contributes to this effectiveness.
Daliresp holds a total of 5 drug patents, out of which 2 have already expired. The remaining patents will expire by March 8, 2024, at the earliest. An important patent to note is US8536206, titled 'Process for the preparation of roflumilast'. After this date, we can expect the release of Daliresp generic. Below are the details of the patent: